Liquidia Corp
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Liquidia Corp is a pharmaceutical company that develops and markets treatments for pulmonary hypertension, including inhaled and oral formulations of treprostinil, using its proprietary PRINT particle engineering technology for drug formulation.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Krepp SarahChief Human Resource Officer | Sell | $19K | 274at $67.76 | Sep 1, 2026 |
| Adair JasonChief Business Officer | Sell | $2.89M | 41,832at $69.09 | Aug 21, 2026 |
| Adair JasonChief Business Officer | Sell | $2.20M | 31,799at $69.09 | Aug 21, 2026 |
| Saggar RajeevChief Medical Officer | Sell | $3.70M | 50,000at $74.06 | Aug 19, 2026 |
| Saggar RajeevChief Medical Officer | Sell | $2.27M | 29,534at $76.84 | Aug 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable LQDA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.